SEC Form 4 · accession 0001636282-26-000111
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Heidy King-Jones
Officer — See Remarks
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 9:34 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2026 | M | 27,999 | $14.50 | A | 30,844 | D | |
| Common StockF3,F2 | Sep 1, 2026 | S | 4,845 | $86.40 | D | 25,999 | D | |
| Common StockF4,F2 | Sep 1, 2026 | S | 16,548 | $87.20 | D | 9,451 | D | |
| Common StockF5,F2 | Sep 1, 2026 | S | 6,206 | $88.17 | D | 3,245 | D | |
| Common StockF2 | Sep 1, 2026 | S | 400 | $89.38 | D | 2,845 | D | |
| Common StockF2 | Sep 2, 2026 | M | 400 | $14.50 | A | 3,245 | D | |
| Common StockF2 | Sep 2, 2026 | S | 400 | $90.00 | D | 2,845 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $14.50 | Sep 1, 2026 | M | 27,999 | D | — | Sep 1, 2033 | Common Stock | 27,999 | 511,811 | D |
| Stock Option (Right to Buy)F6 | $14.50 | Sep 2, 2026 | M | 400 | D | — | Sep 1, 2033 | Common Stock | 400 | 511,411 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
- F2Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.